XFOR Stock: X4 Pharmaceuticals, Inc. Stock Price, Analysis & Insights
Get live xfor stock price $3.73, comprehensive X4 Pharmaceuticals, Inc. stock analysis, charts, news, and expert forecast. Real-time xfor stock data and investment insights.
Loading chart...
Company Overview
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
Company Information
- CEO
- Adam R. Craig
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 143
Contact Information
- Website
- https://www.x4pharma.com
- Address
- 61 North Beacon Street
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Lower volatility stock (Beta: 0.42) may provide portfolio stability
Business Model & Strategy
X4 Pharmaceuticals, Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Adam R. Craig, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
X4 Pharmaceuticals, Inc. competes in the Biotechnology within the broader Healthcare. With 42.6 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Capital Market, X4 Pharmaceuticals, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating X4 Pharmaceuticals, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for X4 Pharmaceuticals, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for X4 Pharmaceuticals, Inc.
- ⚠Investors should consider how X4 Pharmaceuticals, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
42.55M
P/E Ratio
-0.42
Beta
0.42
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 42.55M market capitalization
- Trading Volume: 2.60K shares traded today
- Price Range: 52-week range of $1.35 - $26.82
- Exchange: Listed on NASDAQ Capital Market
Financial Metrics
Market Analysis for X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc. (XFOR) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 42.55M, the company represents a significant player in its market. The stock is currently trading at $3.73 with a positivedaily change of 0.54%.
The company's 143 employee base and presence on the NASDAQ Capital Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -0.42, beta of 0.42, and 52-week price range from $1.35 to $26.82when evaluating investment opportunities.
Why Invest in X4 Pharmaceuticals, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Capital Market)
- • Experienced leadership under Adam R. Craig
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.